Thermo Fisher Scientific Inc. (TMO) Given Average Recommendation of “Buy” by Brokerages

Thermo Fisher Scientific Inc. (NYSE:TMO) has received a consensus rating of “Buy” from the eighteen ratings firms that are currently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating on the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $220.92.

A number of equities research analysts have recently issued reports on TMO shares. Deutsche Bank set a $226.00 target price on shares of Thermo Fisher Scientific and gave the company a “buy” rating in a report on Thursday, October 26th. Zacks Investment Research lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Monday, October 30th. Leerink Swann reiterated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Monday, October 30th. Evercore ISI began coverage on shares of Thermo Fisher Scientific in a research note on Wednesday, January 3rd. They issued an “outperform” rating and a $220.00 price target on the stock. Finally, BTIG Research began coverage on shares of Thermo Fisher Scientific in a research note on Friday, January 5th. They issued a “buy” rating and a $230.00 price target on the stock.

Shares of Thermo Fisher Scientific (NYSE:TMO) traded down $8.88 during mid-day trading on Friday, hitting $198.73. 2,200,000 shares of the stock were exchanged, compared to its average volume of 1,550,000. The company has a debt-to-equity ratio of 0.74, a quick ratio of 0.92 and a current ratio of 1.35. The company has a market cap of $79,270.00, a PE ratio of 35.49, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11. Thermo Fisher Scientific has a 12 month low of $151.69 and a 12 month high of $226.44.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Wednesday, January 31st. The medical research company reported $2.79 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.66 by $0.13. The company had revenue of $6.05 billion for the quarter, compared to analysts’ expectations of $5.72 billion. Thermo Fisher Scientific had a net margin of 10.64% and a return on equity of 16.01%. Thermo Fisher Scientific’s quarterly revenue was up 22.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.41 EPS. research analysts anticipate that Thermo Fisher Scientific will post 10.81 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Monday, April 16th. Investors of record on Thursday, March 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Wednesday, March 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.34%. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.15. Thermo Fisher Scientific’s dividend payout ratio is 10.71%.

In other Thermo Fisher Scientific news, SVP Gregory J. Herrema sold 33,327 shares of the stock in a transaction that occurred on Friday, February 2nd. The shares were sold at an average price of $219.70, for a total transaction of $7,321,941.90. Following the transaction, the senior vice president now owns 60,471 shares in the company, valued at approximately $13,285,478.70. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Marc N. Casper sold 50,000 shares of the stock in a transaction that occurred on Wednesday, November 15th. The stock was sold at an average price of $188.39, for a total transaction of $9,419,500.00. Following the transaction, the chief executive officer now owns 252,577 shares in the company, valued at approximately $47,582,981.03. The disclosure for this sale can be found here. In the last quarter, insiders sold 144,327 shares of company stock worth $28,680,042. 0.49% of the stock is owned by company insiders.

Several large investors have recently made changes to their positions in TMO. Capital Research Global Investors grew its position in shares of Thermo Fisher Scientific by 29.8% during the 2nd quarter. Capital Research Global Investors now owns 17,304,897 shares of the medical research company’s stock worth $3,019,185,000 after purchasing an additional 3,973,136 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Thermo Fisher Scientific by 2,058.1% during the 2nd quarter. Janus Henderson Group PLC now owns 2,342,046 shares of the medical research company’s stock worth $408,620,000 after acquiring an additional 2,233,522 shares in the last quarter. Veritas Asset Management LLP boosted its position in shares of Thermo Fisher Scientific by 112.4% during the 2nd quarter. Veritas Asset Management LLP now owns 2,430,759 shares of the medical research company’s stock worth $424,095,000 after acquiring an additional 1,286,259 shares in the last quarter. Meritage Group LP acquired a new stake in shares of Thermo Fisher Scientific during the 3rd quarter worth approximately $201,383,000. Finally, Capital World Investors boosted its position in shares of Thermo Fisher Scientific by 6.1% during the 2nd quarter. Capital World Investors now owns 11,759,734 shares of the medical research company’s stock worth $2,051,721,000 after acquiring an additional 671,637 shares in the last quarter. Hedge funds and other institutional investors own 86.31% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://sportsperspectives.com/2018/02/09/thermo-fisher-scientific-inc-tmo-given-average-recommendation-of-buy-by-brokerages.html.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.

Analyst Recommendations for Thermo Fisher Scientific (NYSE:TMO)

Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply